Hiroshi Soeda

Learn More
Molecular-targeted therapies require the assessment of targets and their related molecules. Circulating tumour cells (CTCs) are considered a very good source of samples for these purposes. In this study, we applied a practical method for examining CTCs to evaluate the effects of chemotherapy on advanced colorectal cancer (CRC). Even in stage IV CRC, CTCs(More)
BACKGROUND The information provided in patient-centered care and shared decision-making influences patients' concerns and adherence to treatment. In the decision-making process, patients experience decisional conflict. The Decisional Conflict Scale (DCS) is a 16-item, self-administered questionnaire consisting of 5 subscales developed to assess patients'(More)
BACKGROUND Mutations in the KRAS gene have been identified as negative predictors of response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy by patients with metastatic colorectal cancer (mCRC). However, it has been based on the study of mainly Caucasian mCRC patients. This prospective study investigated the relationship between(More)
Anti-epidermal growth factor receptor (EGFR) antibodies, cetuximab, and panitumumab are established as a new treatment option for metastatic colorectal cancer (mCRC). Among activating mutations downstream of EGFR, the KRAS mutation, which is present in 30–45 % of CRC patients, has shown to be a predictive biomarker of resistance to anti-EGFR antibody(More)
BACKGROUND Although dysgeusia is a common adverse event in chemotherapy patients; it has not been evaluated using objective methods, and its prevalence and frequency have not been quantified. METHODS Salt-impregnated taste strips were used to objectively assess dysgeusia in patients receiving chemotherapy at Akita University (n = 38) and those off(More)
EGFR constitute an attractive target for tumor therapy, because it is a transmembrane receptor tyrosine kinase which is critically involved in tumorigenesis by stimulating cell proliferation and inhibiting apoptosis or other biological functions. The anti-tumor effects of targeted therapy by anti-EGFR monoclonal antibodies are mainly based on direct(More)
573 Background: Activating mutation of the KRAS gene is a predictive biomarker for loss of efficacy to anti-EGFR antibody therapy. However, this was mainly established by the evidences of Caucasian studies. Then, this prospective study investigated the role of KRAS mutations on efficacy and safety to cetuximab plus irinotecan in Japanese patients with(More)
The CpG island methylator phenotype (CIMP) with multiple promoter methylated loci has been observed in a subset of human colorectal cancer (CRC) cases. CIMP status, which is closely associated with specific clinicopathological and molecular characteristics, is considered a potential predictive biomarker for efficacy of cancer treatment. However, the(More)
Anti-EGFR antibodies were designed to inhibit the receptor tyrosine kinase activity of EGFR by directly binding to the extracellular domain. Anti-EGFR antibodies have been approved or will be approved for use in Japan, the USA or Europe. Recently, many studies have investigated molecular markers can predict the response to anti-EGFR antibodies so as to(More)